| Identification | Back Directory | [Name]
Etoposide phosphate | [CAS]
117091-64-2 | [Synonyms]
Etopofos
ETOPOPHOS
BMY 40481
ETOPOSIDE PHOSPHATE
ETOPOSIDE PHOSPHONATE
Etoposide 4'-Phosphate
ETOPOSIDEPHOSPHATE,ETOPOPHOS
Etoposide phosphate≥ 98% (HPLC)
ETOPOSIDE PHOSPHONATE, ETOPOPHOS
BMY-40481, Etoposide 4'-Dihydrogenphosphate
(5R,5aR,8aR,9S)-5-[3,5-DiMethoxy-4-(phosphonooxy)phenyl]-9-[[4,6-O-(1R)-ethylidene-β-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one
[5R-[5α,5aβ,8aα,9β(R*)]]-5-[3,5-DiMethoxy-4-(phosphonooxy)phenyl]-9-[(4,6-O-ethylidene-β-D-glucopyranosyl)oxy]-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one
Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5-[3,5-dimethoxy-4-(phosphonooxy)phenyl]-9-[[4,6-O-(1R)-ethylidene-b-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-, (5R,5aR,8aR,9S)-
Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5-[3,5-dimethoxy-4-(phosphonooxy)phenyl]-9-[[4,6-O-(1R)-ethylidene-β-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-, (5R,5aR,8aR,9S)- | [EINECS(EC#)]
630-364-1 | [Molecular Formula]
C29H33O16P | [MDL Number]
MFCD00270859 | [MOL File]
117091-64-2.mol | [Molecular Weight]
668.54 |
| Chemical Properties | Back Directory | [Boiling point ]
907.7±75.0 °C(Predicted) | [density ]
1?+-.0.1 g/cm3(Predicted) | [storage temp. ]
-20°C | [form ]
Solid | [pka]
1.13±0.50(Predicted) | [color ]
White to off-white | [Water Solubility ]
Water: 125 mg/mL (186.97 mM) |
| Hazard Information | Back Directory | [Chemical Properties]
White crystalline powder | [Uses]
As a bioequivalent prodrug of the DNA topoisomerase II inhibitor Etoposide (E933750), Etoposide phosphate can be used in the treatment of a wide variety of hematological malignancies and solid tumors.
| [Definition]
ChEBI: Etoposide phosphate is a furonaphthodioxole. | [Brand name]
Etopophos (Bristol-Myers
Squibb). | [in vivo]
Etoposide phosphate (intravenous injection; 50, 100, or 150 mg/kg; single dose) has clinical symptomology of progressive ataxia, impaired righting reflex, and splaying and paresis of fore- and hindlimbs at day 8?in female CD-1 mice[3]. | Animal Model: | Female CD-1 mice[3] | | Dosage: | 50, 100, or 150 mg/kg | | Administration: | Intravenous injection; single dose | | Result: | Observed degeneration of dorsal root ganglion cells and axonal degeneration of their distal and proximal processes in peripheral nerves, dorsal spinal roots, and dorsal funiculi of the spinal cord at all doses under light microscopy (LM). |
| [IC 50]
Topoisomerase II |
|
|